There’s fear the “second wave” of the coronavirus is already here.
In fact, new cases and hospitalizations are aggressively sweeping across Florida, California, Texas, Alaska, Arkansas, Kentucky, Mississippi, North Carolina, Oregon, and South Carolina.
Worse, according to former FDA chief Dr. Scott Gottlieb, coronavirus hot spots “could quickly get out of control.”
Thankfully, we may be nearing potential vaccines.
Not only did Moderna Inc. (MRNA) just advance late-stage development of its vaccine, and finalize its Phase 3 study protocol, Canadian biopharmaceutical company Edesa Biotech (EDSA) just announced regulatory approval for its late-stage study.
According to the company, it “has received expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, which the company is developing as a potential treatment for moderate to severe COVID-19 patients. The company reported that it has EB05 drug product available now and is seeking government grants to accelerate the initiation and rollout of the study, beginning at up to 30 sites.”
“Health Canada’s expedited review process and subsequent approval of our Clinical Trial Application represents a significant step in developing new drugs that can treat the underlying conditions induced by the SARS-CoV-2 infection,” said Dr. Par Nijhawan, Chief Executive Officer of Edesa. “We greatly appreciate the actions being taken by the government to expedite COVID-19 applications and provide support for clinical studies.”